Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Mass General Brigham Inc | 12 |
| 2 | Massachusetts Institute of Technology | 10 |
| 3 | Takeda Pharmaceutical Co Ltd | 10 |
| 4 | Harvard University | 9 |
| 5 | Bayer AG | 7 |
| 6 | GSK PLC | 6 |
| 7 | Sumitomo Chemical Co Ltd | 5 |
| 8 | Leland Stanford Junior University | 3 |
| 9 | Boston University | 2 |
| 10 | Children's Hospital of Philadelphia | 2 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 57 |
| 2 | A61P | Therapeutic activity (drug indications) | 53 |
| 3 | C07D | Heterocyclic compounds | 39 |
| 4 | C07C | Acyclic and carbocyclic compounds | 25 |
| 5 | C07K | Peptides | 19 |
| 6 | C12N | Microorganisms, enzymes | 19 |
| 7 | G01N | Investigating / analysing materials | 14 |
| 8 | C12Q | Measuring/testing involving enzymes | 11 |
| 9 | A01N | Preservation of bodies; biocides; pest repellents | 8 |
| 10 | B01J | Chemical/physical processes (e.g. catalysts) | 7 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Application of safrole oxide in the growth and death of vascular endothelial cell | 2002 | 2 | |
| Application of safrole oxide in endothelial cell and nerve cell culturing system | 2008 | 0 | |
| Application of safrole oxide in endothelial cell and nerve cell culturing system | 2007 | 0 | |
| Alkoxy derivative of safrole oxide 2-alkoxy-piperonyl ethanol and its prepn and application | 2004 | 0 | |
| Alkoxy derivative of safrole oxide 2-alkoxy-piperonyl ethanol and its prepn and application | 2002 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Bao‐Xiang Zhao | Shanghai Institute of Organic Chemistry | 14 |
| 2 | Jun‐Ying Miao | Shandong University | 13 |
| 3 | Jing Zhao | Shandong University | 10 |
| 4 | Le Su | Shandong University | 8 |
| 5 | ShangLi Zhang | Shandong University | 7 |
| 6 | Aiying Du | Shandong University | 5 |
| 7 | Shangli Zhang | Shandong University | 4 |
| 8 | Wen‐Sheng Chung | National Yang Ming Chiao Tung University | 3 |
| 9 | Su‐Yin Chiang | China Medical University | 3 |
| 10 | Deling Yin | East Tennessee State University | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. | 1983 | 422 | Genomics, phytochemicals, and oxidative stress |
| The side-chain epoxidation and hydroxylation of the hepatocarcinogens safrole and estragole and some related compounds by rat and mouse liver microsomes | 1981 | 62 | Pharmacogenetics and Drug Metabolism |
| Photometric assay of hepatic epoxide hydrolase activity with safrole oxide (SAFO) as substrate | 1974 | 62 | Pharmacogenetics and Drug Metabolism |
| Upregulating of Fas, integrin β4 and P53 and depressing of PC‐PLC activity and ROS level in VEC apoptosis by safrole oxide | 2005 | 49 | Antioxidant Activity and Oxidative Stress |
| Covalent binding to DNA in vitro of 2',3'-oxides derived from allylbenzene analogs. | 1996 | 48 | DNA and Nucleic Acid Chemistry |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of safrole oxide?
Which organizations hold the most patents for safrole oxide?
How has patent activity for safrole oxide changed in recent years?
What research topics are covered by published papers on safrole oxide?
What are the primary patent classification areas for safrole oxide inventions?